References
- Goldfarb S, Mccullough P, Mcdermott J, Gay S. Contrast-induced acute kidney injury: Specialty-specific protocols for interventional radiology, diagnostic computed tomography radiology, and interventional cardiology. Mayo Clin Proc. 2009;84(2):170–179
- Mehran R, Nikolsky E. Contrast-induced nephropathy: Definition, epidemiology, and patients at risk. Kidney Int Suppl. 2006;100:11–15
- McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med. 1997;103(5):368–375
- Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. Int J Cardiol. 2012;158(2):186–192
- Heyman SN, Rosenberger C, Rosen S. Regional alterations in renal hemodynamics and oxygenation: A role in contrast medium-induced nephropathy. Nephrol Dial Transplant. 2005;20:6–11
- Aydoğdu S. Contrast-induced nephropathy. Turk Kardiyol Dern Ars. 2013;41(1):28–30
- Romano G, Briguori C, Quintavalle C, et al. Contrast agents and renal cell apoptosis. Eur Heart J. 2008;29(20):2569, 7631–7634
- Yenicerioglu Y, Yilmaz O, Sarioglu S, et al. Effects of N-acetylcysteine on radio contrast nephropathy in rats. Scand J Urol Nephrol. 2006;40:63–69
- Marenzi G, Assanelli E, Marana I, et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354:2773–2782
- Oelze M, Daiber A, Brandes RP, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677–684
- Toprak O, Cirit M, Tanrisev M, et al. Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant. 2008;23:853–859
- Talke H, Schubert GE. Enzymatic urea determination in the blood and serum in the Warburg optical test. Klin Wochenschr. 1965;43:174–175
- Fabiny DL, Ertingshausen G. Automated reaction-rate method for determination of serum creatinine with the Centrifi Chem. Clin Chem. 1971;17:696–700
- Esterbauer H, Cheeseman KH. Determination of aldehydic lipid peroxidation products: Malonaldehyde and 4-hidroxynonenal. Methods Enzymol. 1990;186:407–421
- Lowry O, Rosenbraugh N, Farr L, Rondall R. Protein measurement with the Folin-phenol reagent. J Biol Chem. 1951;193(1):265–275
- Erel O. A novel automated direct measurement method for total antioxidant capacity using a new generation more stabile ABTS radicalcation. Clin Biochem. 2004;37:277–285
- Sun Y, Oberley LW, Li Y. A simple method for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497–500
- Akgüllü Ç, Saruhan T, Eryilmaz U, et al. The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy. Ren Fail. 2014;İ36:575–580
- Boyacıoglu M, Turgut H, Akgullu C, Eryılmaz U, Kum C, Onbasılı OA. The effect of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rats. J Vet Med Sci. 2014;76:1–8
- Pannu N, Wiebe N, Tonelli M. Alberta kidney disease network, prophylaxis strategies for contrast-induced nephropathy. JAMA. 2006;295:2765–2779
- Spargias K, Alexopoulos E, Kyrzopoulos S, et al. Ascorbic acid prevents contrast-mediated nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. Circulation. 2004;110:2837–2842
- Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: state of the art. Nephrol Dial Transplant. 2005;20:1542–1550
- Toprak O, Cirit M. Risk factors for contrast-induced nephropathy. Kidney Blood Press Res. 2006;29:84–93
- Deray G, Baumelou B, Martinez F, Brillet G, Jacobs C. Renal vasoconstriction after low and high osmolar contrast agents in ischemic and nonischemic canine kidney. Clin Nephrol. 1991;36:93–96
- Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med. 2000;109:665–678
- Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med. 1996;334:1448–1460
- Paller MS. The cell biology of reperfusion injury in the kidney. J Investig Med. 1994;42:632–639
- Avunduk MC, Yurdakul T, Erdemli E, Yavuz A. Prevention of renal damage by alpha tocopherol in ischemia and reperfusion models of rats. Urol Res. 2003;31:280–285
- Dandona P, Ghanim H, Brooks DP. Antioxidant activity of carvedilol in cardiovascular disease. J Hypertens. 2007;25:731–741
- Yue TL, Mckenna PJ, Gu JL, Cheng HY, Ruffolo RR Jr, Feuerstein GZ. Carvedilol, a new antihypertensive agent, prevents lipid peroxidation and oxidative injury to endothelial cells. Hypertension. 1993;22:922–928
- Singh D, Chander V, Chopra K. Carvedilol attenuates ischemia–reperfusion induced oxidative renal injury in rats. Fundam Clin Pharmacol. 2004;18:627–634
- Akbas H, Ozden M, Kanko M, et al. Protective antioxidant effects of carvedilol in a rat model of ischemia-reperfusion injury. J Int Med Res. 2005;33:528–536
- Hayashi T, De Velasco MA, Saitou Y, et al. Carvedilol protects tubular epithelial cells from ischemia-reperfusion injury by inhibiting oxidative stress. Int J Urol. 2010;17:989–995
- Oettl K, Greilberger J, Zangger K, Haslinger E, Reibnegger G, Jürgens G. Radical-scavenging and iron-chelating properties of carvedilol, an antihypertensive drug with antioxidative activity. Biochem Pharmacol. 2001;62:241–248
- Noguchi N, Nishino K, Niki E. Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation. Biochem Pharmacol. 2000;59:1069–1076
- Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Drug Metab Rev. 1999;31:971–997
- Feng MG, Prieto MC, Navar LG. Nebivolol-induced vasodilation of renal afferent arterioles involves β3-adrenergic receptor and nitric oxide synthase activation. Am J Physiol Renal Physiol. 2012;303(5):775–782
- Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res. 2001;49:430–439
- Pires MJ, Rodríguez-Peña AB, Arévalo M, et al. Long-term nebivolol administration reduces renal fibrosis and prevents endothelial dysfunction in rats with hypertension induced by renal mass reduction. J Hypertens. 2007;25:2486–2496
- Greven J, Gabriëls G. Effect of nebivolol, a novel beta 1-selective adrenoceptor antagonist with vasodilating properties, on kidney function. Arzneimittelforschung. 2000;50:973–979
- Akgüllü C, Eryılmaz U, Güngör H, Huyut A, Zencir C, Hekim T. A clinical study about contrast nephropathy: Risk factors and the role of beta blockers. Anadolu Kardiyol Derg. 2014 Apr 28. doi: 10.5152/akd.2014.5304. [Epub ahead of print]